Mixed Large Cell Neuroendocrine Carcinoma and Adenocarcinoma of the Cervix: A Rare Entity.

Int J Surg PatholMay 7, 2026 (epub)
Case ReportOncology (Medical)Obstetrics & Gynecology

Zheng Guona, Shi Yabin, Du Qian et al.

✦ AI-curated · Sources linked

Case in brief

A patient presented with a rare mixed tumor of the cervix, comprising large cell neuroendocrine carcinoma and adenocarcinoma. Molecular analysis revealed the presence of HPV18 DNA in both tumor components. Two years post-diagnosis, the neuroendocrine component progressed to cervical lymph node metastasis, highlighting its aggressive nature and poor prognosis.

Diagnostic / clinical pearl

Clinicians should be vigilant in identifying the large cell neuroendocrine carcinoma component in cervical cancer due to its propensity for early metastasis and associated poor outcomes.

Why it matters

This case underscores the importance of molecular characterization in cervical tumors, particularly regarding the role of HPV in tumor pathology and the need for tailored treatment strategies.

Source

PubMed · PMID 42095541

Published in Int J Surg Pathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.